These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 8355187

  • 1. The in vivo antiplatelet effects of thromboxane A2 synthase inhibitors are potentiated by simultaneous thromboxane A2/prostaglandin H2 receptor blockade.
    Golino P, Ambrosio G, Gresele P, Pascucci I, Ragni M, Russolillo E, Leproux GB, Chiariello M.
    J Pharmacol Exp Ther; 1993 Aug; 266(2):511-7. PubMed ID: 8355187
    [Abstract] [Full Text] [Related]

  • 2. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P, Ambrosio G, Villari B, Ragni M, Focaccio A, Pace L, de Clerk F, Condorelli M, Chiariello M.
    J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F, Colombo M, Pierucci L, Volpi D, Dho L, Ukmar G, Rosa B, Salvati P.
    Drugs Exp Clin Res; 1993 Feb; 19(6):249-60. PubMed ID: 8013268
    [Abstract] [Full Text] [Related]

  • 6. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P, Dho L, Ukmar G, Vaga L, Rimoldi O, Patrono C.
    J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
    [Abstract] [Full Text] [Related]

  • 7. Thromboxane A2/prostaglandin endoperoxide (TXA2/PG-END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor--TXA2/PG-END receptor antagonist.
    Heylen L, De Clerck F, Somers Y, Leysen JE.
    Blood Coagul Fibrinolysis; 1991 Oct; 2(5):617-21. PubMed ID: 1838285
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
    Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J.
    J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
    [Abstract] [Full Text] [Related]

  • 10. In vivo effects of a novel thromboxane A2/prostaglandin H2 (TXA2/PGH2) partial agonist, (+)5(Z)-7-[3-endo-phenylsulfonylamino[2.2.1]- bicyclohept-2-exo-yl]-heptenoic acid [(+)-S-145], on vascular, platelet and cardiac function.
    Dubé GP, Jakubowski JA, Brune KA, Bemis KG, Kurtz WL.
    J Pharmacol Exp Ther; 1995 Feb; 272(2):799-807. PubMed ID: 7853197
    [Abstract] [Full Text] [Related]

  • 11. Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations.
    Yao SK, Rosolowsky M, Anderson HV, Golino P, NcNatt JM, De Clerck F, Buja LM, Willerson JT.
    J Am Coll Cardiol; 1990 Sep; 16(3):705-13. PubMed ID: 2143767
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
    Bertele V, De Gaetano G.
    Eur J Pharmacol; 1982 Dec 03; 85(3-4):331-3. PubMed ID: 6295787
    [Abstract] [Full Text] [Related]

  • 15. Actions of the E2-isoprostane, 8-ISO-PGE2, on the platelet thromboxane/endoperoxide receptor in humans and rats: additional evidence for the existence of a unique isoprostane receptor.
    Longmire AW, Roberts LJ, Morrow JD.
    Prostaglandins; 1994 Oct 03; 48(4):247-56. PubMed ID: 7878192
    [Abstract] [Full Text] [Related]

  • 16. Cooperative mediation by serotonin S2 and thromboxane A2/prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses.
    Ashton JH, Ogletree ML, Michel IM, Golino P, McNatt JM, Taylor AL, Raheja S, Schmitz J, Buja LM, Campbell WB.
    Circulation; 1987 Oct 03; 76(4):952-9. PubMed ID: 3652429
    [Abstract] [Full Text] [Related]

  • 17. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
    Vezza R, Mezzasoma AM, Venditti G, Gresele P.
    Thromb Haemost; 2002 Jan 03; 87(1):114-21. PubMed ID: 11848439
    [Abstract] [Full Text] [Related]

  • 18. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
    Weber C, Beetens JR, Tegtmeier F, Van Rooy P, Vercammen E, Wouters L, De Clerck F.
    Thromb Haemost; 1992 Aug 03; 68(2):214-20. PubMed ID: 1412169
    [Abstract] [Full Text] [Related]

  • 19. "In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets.
    Berrettini M, De Cunto M, Parise P, Grasselli S, Nenci GG.
    Eur J Clin Pharmacol; 1990 Aug 03; 39(5):495-500. PubMed ID: 1963845
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists.
    Ashton JH, Schmitz JM, Campbell WB, Ogletree ML, Raheja S, Taylor AL, Fitzgerald C, Buja LM, Willerson JT.
    Circ Res; 1986 Nov 03; 59(5):568-78. PubMed ID: 3542279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.